Surrozen, Inc.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-24.42%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float30.73M Perf Month-24.42%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-87.81%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-87.96%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.14 - 3.00 Perf YTD-83.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-93.70% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low34.96% ATR0.07
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)37.44 Volatility11.83% 19.28%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.00 Prev Close0.19
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume16.34K Price0.19
Recom- SMA20-29.48% SMA50-73.74% SMA200-83.78% Volume0 Change0.00%
May-16-22 08:00AM  
May-11-22 08:00AM  
May-05-22 08:00AM  
May-02-22 08:00AM  
Mar-24-22 08:00AM  
Jan-10-22 08:00AM  
Jan-05-22 08:00AM  
Nov-15-21 04:00PM  
Nov-11-21 10:51AM  
Nov-05-21 08:00AM  
Oct-05-21 04:30PM  
Sep-23-21 08:30AM  
Aug-11-21 05:30PM  
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.